JHL Biotech, Inc., a contract biologics manufacturer based in Hsinchu, Taiwan, has entered into a contract manufacturing master service agreement with Affinita Biotech, a South San Francisco, California-based preclinical stage biotechnology company The agreement covers a development and manufacturing partnership for Affinita's oncology monoclonal antibodies.

The agreement, extending to 2020, is estimated to be worth up to $20 million in value. JHL will provide cell-line development, process development, and manufacturing expertise. The activities will be carried out in JHL’s Zhubei site in Taiwan as well as at JHL's manufacturing facility in Wuhan, China.

Source; JHL Biotech